Eye experts warn people not to take pictures of March 20 solar eclipse on a smartphone because of blindness risk.
The danger comes as people look directly at the Sun as they position themselves for selfies or other shots.
Inadvertently, glancing at the Sun – even briefly while setting up a shot – can lead to burns at the back of eye.
Experts advise indirect viewing, using pinholes and facing away from the Sun.
For many, this will be the first time they have witnessed the phenomenon in 15 years, but eye specialists say people should not use their camera phones to capture the event.
The safest ways to view the eclipse include using a pinhole camera to project an image of the eclipse on to a piece of card.
Other options involve using colanders to make multiple pinholes or using specifically designed eclipse viewing glasses.
Experts warn the glasses must be checked for damage first and should be put on before looking up at the sky.
It’s a Total Solar Eclipse in the Faroe Islands and Svalbard (Norway), and a Partial Solar Eclipse in Europe, northern and eastern Asia and northern and western Africa. The eclipse starts at 07:41 UTC and ends at 11:50 UTC.
The sky will darken but the Sun will still peek out from behind the Moon.
[youtube rDaqNvjYjUk 650]
US researchers revealed that three people who lost their sight in childhood have reported a dramatic improvement in vision after having gene therapy in both eyes.
There was some improvement after the genetic fault in one eye was corrected four years ago.
Now, one woman has described her joy at seeing her children’s faces, after her second eye was treated.
The three have Leber’s Congenital Amaurosis (LCA), a rare inherited disease caused by defects in a gene encoding a protein needed for vision.
It appears at birth or in the first months of life, leading to severely impaired vision, involuntary eye movements and poor night vision.
LCA disorder, which can be caused by “mistakes” in more than 10 different genes, prevents normal function of the retina; the light-sensitive layer of cells at the back of the eye.
Several teams around the world are carrying out early trials of gene therapy in blindness, including experts at the Philadelphia Children’s Hospital and the University of Philadelphia, US.
Only a handful of patients worldwide have received the treatment to boost a faulty gene underlying an inherited form of blindness.
The US researchers revealed in 2008 that 12 people with LCA had recovered some vision after being injected in one eye with an engineered virus carrying the gene RPE65.
In a follow-up study they treated the other eye of three of them, and found it improved their sight even more.
The subjects could see better in dim light and two were able to find their way around obstacles.
The results were revealed in the latest edition of the journal Science Translational Medicine.
The principal investigator of the study, Dr. Jean Bennett, said the patients could now do things they could never do before, such as walking around at night, going shopping for groceries and recognizing people’s faces.
Dr. Jean Bennett said: “We’ve shown that it is possible to safely treat both eyes of people with this particular form of retinal deficiency using a gene-based treatment and further we’ve demonstrated that the brain understands what the retina is seeing.”
MRI scans showed the brain could “see” the newly-treated eye.
Dr. Manzar Ashtari, from The Children’s Hospital of Philadelphia, who carried out the brain scans, said: “We saw the brain gets activated – the brain after treatment responded to the visual stimuli.”
One of the three patients who took part in the clinical trial, Tami Morehouse, told how her vision gradually returned, opening up a whole new world for her.
Even though she can’t see well enough to read or drive a car, she can now make-out her children’s faces, watch them play baseball and see the light change over Lake Erie, where she lives.
Tami Morehouse said: “Life is so much easier at a level that most people take for granted. Any amount of vision that you can get when you have almost nothing is incredibly valuable.”
The researchers now hope to treat the second eye of the remaining nine patients, and extend the clinical trial.
Dr. Jean Bennett said: “I think it will be a stepping stone to treating more common forms of blindness in both eyes.”
